Glioblastoma multiforme (GBM) is a highly aggressive, complex, and devastating form of brain cancer, effecting hundreds of people each day. We believe it is our duty to accelerate progress against this disease so we launched the Defeat GBM Research Collaborative in 2013 with the intent to double the 5 year survival rate of GBM patients. This comes at a time when collaboration is becoming the norm and the abundance of genomic data is accelerating diagnostic, prognostic, and therapeutic progress.
Oligo Research Fund
Oligodendroglioma (oligo) is a relatively rare brain tumor representing about 6% of gliomas, with a diagnosis rate of about 1,150 patients a year in the U.S. alone. Critical research is required to deliver oligo patients new therapies that are more durable and extend their lives. In order to make effective, targeted therapies a reality it is essential to identify and understand the molecular drivers of the tumor’s genesis and maintenance, as well as resistance.
Our new pediatric initiative, Project Impact, will leverage increases in knowledge gained from earlier funded research efforts, and develop a program that can address critical barriers to progress within the drug discovery and development pipeline through an integrated approach to advance research toward new treatments for pediatric brain tumor patients.
The Community Research Fund allows contributors to pool donations to support research on a specific type of tumor. This program leverages a team of highly experienced, nationally-recognized scientific experts, working with National Brain Tumor Society staff, to determine the best investment strategy for each fund.
From the Blog
April 11, 2014
Recently in Brain Tumor Research…
…A round-up of recent news important to the brain tumor community New Revelations on Relationship Between Low- and High-grade Gliomas A comprehensive genomic analysis of low-grade gliomas (grade II and III astrocytomas, oligodendrogliomas, and mixed gliomas) of The Cancer Genome Atlas brain tumor studies found that low-grade gliomas can be sorted into three categories based [...]Read more |
March 31, 2014
Reasons to Run: Brooke Howitt, MD, competes in the Boston Marathon to fight brain tumors
On Patriots Day, April 21, 2014, runners from across the globe will compete in the annual Boston Marathon, one of the most renowned running competitions in the world. This year, the National Brain Tumor Society was fortunate enough to receive a number from the town of Newton, and we are excited to provide our number [...]Read more |
March 27, 2014
Project Impact Gets to Work: Removing Barriers to Pediatric Cancer Treatments
The choice of when to push change in a broken system, “depends largely on timing, opportunity, and the leverage of the people initiating the change,” according to popular theories in system change. Moreover, to achieve systems change leaders must, “bring people addressing parts of the problem around the same table,” and by “…inviting new people [...]Read more |